Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

By S. Julius, S. Kjeldsen, M. Weber, H. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G. Mcinnes, Lada Mitchell and 4 more. The Lancet, 2004

2,565 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/25995f7de2e8c2d8500336487f712bf84b468bc4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. F. Cosentino
2. Joshua A. Beckman
3. F. Paneni
4. M. Creager

In Endocrinology, Diabetes and Metabolism

1. F. Cosentino
2. Joshua A. Beckman
3. F. Paneni
4. M. Creager

Citations in the corpus

• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, methodology): “ACE inhibitors, ARBs [691, 1172] and long-acting dihydropyridine CCBs improve insulin sensitivity and exert no”
• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, background): “for the endpoint of cardiovascular morbidity and mortality in hypertensive diabetic patients.(107) The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)(108)”